Research Analysts Offer Predictions for HRMY Q2 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Harmony Biosciences in a research report issued on Monday, July 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $1.11 per share for the quarter, up from their prior forecast of $0.68. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.30 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q3 2026 earnings at $1.00 EPS and FY2026 earnings at $3.54 EPS.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). The business had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period last year, the business earned $0.78 earnings per share.

Several other equities analysts have also recently weighed in on HRMY. Deutsche Bank Aktiengesellschaft increased their price target on Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a report on Tuesday, June 30th. Truist Financial upped their price objective on Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Finally, Weiss Ratings upgraded shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.50.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $34.86 on Wednesday. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average price of $33.74 and a 200-day moving average price of $32.62. Harmony Biosciences has a 52 week low of $25.52 and a 52 week high of $40.87. The firm has a market capitalization of $2.02 billion, a PE ratio of 14.06, a P/E/G ratio of 0.34 and a beta of 0.94.

Institutional Investors Weigh In On Harmony Biosciences

Several institutional investors and hedge funds have recently modified their holdings of HRMY. Amundi grew its stake in Harmony Biosciences by 115.6% during the first quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after acquiring an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Harmony Biosciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock valued at $752,000 after buying an additional 984 shares during the last quarter. Empowered Funds LLC purchased a new position in Harmony Biosciences during the 1st quarter valued at approximately $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Harmony Biosciences by 53.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after acquiring an additional 33,058 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in Harmony Biosciences by 9.8% in the 2nd quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock worth $266,000 after acquiring an additional 748 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.